Global Malignant Glioma Therapeutics Market Size, Status and Forecast 2020-2026

August 2020 | 94 pages | ID: G0D812CF93EBEN
QYResearch

Abstracts

This report focuses on the global Malignant Glioma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Malignant Glioma Therapeutics development in North America, Europe and Asia-Pacific.

The key players covered in this study

• Merck
• Roche
• Arbor Pharmaceuticals
• Pfizer
• AbbVie
• Amgen
• Bristol-Myers Squibb
• Sun Pharmaceuticals
• Teva
• Emcure

Market segment by Type, the product can be split into

• Chemotherapy
• Radiotherapy
• Targeted therapy

Market segment by Application, split into

• Adult
• Children

Market segment by Regions/Countries, this report covers

• North America
• Europe
• Asia-Pacific

The study objectives of this report are:

• To analyze global Malignant Glioma Therapeutics status, future forecast, growth opportunity, key market and key players.
• To present the Malignant Glioma Therapeutics development in North America, Europe and Asia-Pacific.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Malignant Glioma Therapeutics are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Malignant Glioma Therapeutics Revenue
1.4 Market Analysis by Type
  1.4.1 Global Malignant Glioma Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Chemotherapy
  1.4.3 Radiotherapy
  1.4.4 Targeted therapy
1.5 Market by Application
  1.5.1 Global Malignant Glioma Therapeutics Market Share by Application: 2020 VS 2026
  1.5.2 Adult
  1.5.3 Children
1.6 Coronavirus Disease 2019 (Covid-19): Malignant Glioma Therapeutics Industry Impact
  1.6.1 How the Covid-19 is Affecting the Malignant Glioma Therapeutics Industry
    1.6.1.1 Malignant Glioma Therapeutics Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Malignant Glioma Therapeutics Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Malignant Glioma Therapeutics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Malignant Glioma Therapeutics Market Perspective (2015-2026)
2.2 Malignant Glioma Therapeutics Growth Trends by Regions
  2.2.1 Malignant Glioma Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Malignant Glioma Therapeutics Historic Market Share by Regions (2015-2020)
  2.2.3 Malignant Glioma Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Malignant Glioma Therapeutics Market Growth Strategy
  2.3.6 Primary Interviews with Key Malignant Glioma Therapeutics Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Malignant Glioma Therapeutics Players by Market Size
  3.1.1 Global Top Malignant Glioma Therapeutics Players by Revenue (2015-2020)
  3.1.2 Global Malignant Glioma Therapeutics Revenue Market Share by Players (2015-2020)
  3.1.3 Global Malignant Glioma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Malignant Glioma Therapeutics Market Concentration Ratio
  3.2.1 Global Malignant Glioma Therapeutics Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Malignant Glioma Therapeutics Revenue in 2019
3.3 Malignant Glioma Therapeutics Key Players Head office and Area Served
3.4 Key Players Malignant Glioma Therapeutics Product Solution and Service
3.5 Date of Enter into Malignant Glioma Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Malignant Glioma Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Malignant Glioma Therapeutics Forecasted Market Size by Type (2021-2026)

5 MALIGNANT GLIOMA THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Malignant Glioma Therapeutics Market Size by Application (2015-2020)
5.2 Global Malignant Glioma Therapeutics Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Malignant Glioma Therapeutics Market Size (2015-2020)
6.2 Malignant Glioma Therapeutics Key Players in North America (2019-2020)
6.3 North America Malignant Glioma Therapeutics Market Size by Type (2015-2020)
6.4 North America Malignant Glioma Therapeutics Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Malignant Glioma Therapeutics Market Size (2015-2020)
7.2 Malignant Glioma Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Malignant Glioma Therapeutics Market Size by Type (2015-2020)
7.4 Europe Malignant Glioma Therapeutics Market Size by Application (2015-2020)

8 ASIA-PACIFIC

8.1 Asia-Pacific Malignant Glioma Therapeutics Market Size (2015-2020)
8.2 Malignant Glioma Therapeutics Key Players in Asia-Pacific (2019-2020)
8.3 Asia-Pacific Malignant Glioma Therapeutics Market Size by Type (2015-2020)
8.4 Asia-Pacific Malignant Glioma Therapeutics Market Size by Application (2015-2020)
(2015-2020)
(2015-2020)

9 KEY PLAYERS PROFILES

9.1 Merck
  9.1.1 Merck Company Details
  9.1.2 Merck Business Overview and Its Total Revenue
  9.1.3 Merck Malignant Glioma Therapeutics Introduction
  9.1.4 Merck Revenue in Malignant Glioma Therapeutics Business (2015-2020))
  9.1.5 Merck Recent Development
9.2 Roche
  9.2.1 Roche Company Details
  9.2.2 Roche Business Overview and Its Total Revenue
  9.2.3 Roche Malignant Glioma Therapeutics Introduction
  9.2.4 Roche Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.2.5 Roche Recent Development
9.3 Arbor Pharmaceuticals
  9.3.1 Arbor Pharmaceuticals Company Details
  9.3.2 Arbor Pharmaceuticals Business Overview and Its Total Revenue
  9.3.3 Arbor Pharmaceuticals Malignant Glioma Therapeutics Introduction
  9.3.4 Arbor Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.3.5 Arbor Pharmaceuticals Recent Development
9.4 Pfizer
  9.4.1 Pfizer Company Details
  9.4.2 Pfizer Business Overview and Its Total Revenue
  9.4.3 Pfizer Malignant Glioma Therapeutics Introduction
  9.4.4 Pfizer Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.4.5 Pfizer Recent Development
9.5 AbbVie
  9.5.1 AbbVie Company Details
  9.5.2 AbbVie Business Overview and Its Total Revenue
  9.5.3 AbbVie Malignant Glioma Therapeutics Introduction
  9.5.4 AbbVie Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.5.5 AbbVie Recent Development
9.6 Amgen
  9.6.1 Amgen Company Details
  9.6.2 Amgen Business Overview and Its Total Revenue
  9.6.3 Amgen Malignant Glioma Therapeutics Introduction
  9.6.4 Amgen Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.6.5 Amgen Recent Development
9.7 Bristol-Myers Squibb
  9.7.1 Bristol-Myers Squibb Company Details
  9.7.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  9.7.3 Bristol-Myers Squibb Malignant Glioma Therapeutics Introduction
  9.7.4 Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.7.5 Bristol-Myers Squibb Recent Development
9.8 Sun Pharmaceuticals
  9.8.1 Sun Pharmaceuticals Company Details
  9.8.2 Sun Pharmaceuticals Business Overview and Its Total Revenue
  9.8.3 Sun Pharmaceuticals Malignant Glioma Therapeutics Introduction
  9.8.4 Sun Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.8.5 Sun Pharmaceuticals Recent Development
9.9 Teva
  9.9.1 Teva Company Details
  9.9.2 Teva Business Overview and Its Total Revenue
  9.9.3 Teva Malignant Glioma Therapeutics Introduction
  9.9.4 Teva Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.9.5 Teva Recent Development
9.10 Emcure
  9.10.1 Emcure Company Details
  9.10.2 Emcure Business Overview and Its Total Revenue
  9.10.3 Emcure Malignant Glioma Therapeutics Introduction
  9.10.4 Emcure Revenue in Malignant Glioma Therapeutics Business (2015-2020)
  9.10.5 Emcure Recent Development

10 ANALYST'S VIEWPOINTS/CONCLUSIONS

11 APPENDIX

11.1 Research Methodology
  11.1.1 Methodology/Research Approach
  11.1.2 Data Source
11.2 Disclaimer
11.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Malignant Glioma Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Malignant Glioma Therapeutics Revenue
Table 3. Ranking of Global Top Malignant Glioma Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Malignant Glioma Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Radiotherapy
Table 7. Key Players of Targeted therapy
Table 8. COVID-19 Impact Global Market: (Four Malignant Glioma Therapeutics Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Malignant Glioma Therapeutics Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Malignant Glioma Therapeutics Players to Combat Covid-19 Impact
Table 13. Global Malignant Glioma Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global Malignant Glioma Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global Malignant Glioma Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global Malignant Glioma Therapeutics Market Share by Regions (2015-2020)
Table 17. Global Malignant Glioma Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global Malignant Glioma Therapeutics Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. Malignant Glioma Therapeutics Market Growth Strategy
Table 23. Main Points Interviewed from Key Malignant Glioma Therapeutics Players
Table 24. Global Malignant Glioma Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 25. Global Malignant Glioma Therapeutics Market Share by Players (2015-2020)
Table 26. Global Top Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Therapeutics as of 2019)
Table 27. Global Malignant Glioma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players Malignant Glioma Therapeutics Product Solution and Service
Table 30. Date of Enter into Malignant Glioma Therapeutics Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 33. Global Malignant Glioma Therapeutics Market Size Share by Type (2015-2020)
Table 34. Global Malignant Glioma Therapeutics Revenue Market Share by Type (2021-2026)
Table 35. Global Malignant Glioma Therapeutics Market Size Share by Application (2015-2020)
Table 36. Global Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 37. Global Malignant Glioma Therapeutics Market Size Share by Application (2021-2026)
Table 38. North America Key Players Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 39. North America Key Players Malignant Glioma Therapeutics Market Share (2019-2020)
Table 40. North America Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 41. North America Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 42. North America Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 43. North America Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 44. Europe Key Players Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players Malignant Glioma Therapeutics Market Share (2019-2020)
Table 46. Europe Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 47. Europe Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 48. Europe Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 49. Europe Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 50. Asia-Pacific Key Players Malignant Glioma Therapeutics Revenue (2019-2020) (Million US$)
Table 51. Asia-Pacific Key Players Malignant Glioma Therapeutics Market Share (2019-2020)
Table 52. Asia-Pacific Malignant Glioma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 53. Asia-Pacific Malignant Glioma Therapeutics Market Share by Type (2015-2020)
Table 54. Asia-Pacific Malignant Glioma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 55. Asia-Pacific Malignant Glioma Therapeutics Market Share by Application (2015-2020)
Table 56. Merck Company Details
Table 57. Merck Business Overview
Table 58. Merck Product
Table 59. Merck Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 60. Merck Recent Development
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Product
Table 64. Roche Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 65. Roche Recent Development
Table 66. Arbor Pharmaceuticals Company Details
Table 67. Arbor Pharmaceuticals Business Overview
Table 68. Arbor Pharmaceuticals Product
Table 69. Arbor Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 70. Arbor Pharmaceuticals Recent Development
Table 71. Pfizer Company Details
Table 72. Pfizer Business Overview
Table 73. Pfizer Product
Table 74. Pfizer Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 75. Pfizer Recent Development
Table 76. AbbVie Company Details
Table 77. AbbVie Business Overview
Table 78. AbbVie Product
Table 79. AbbVie Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 80. AbbVie Recent Development
Table 81. Amgen Company Details
Table 82. Amgen Business Overview
Table 83. Amgen Product
Table 84. Amgen Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 85. Amgen Recent Development
Table 86. Bristol-Myers Squibb Company Details
Table 87. Bristol-Myers Squibb Business Overview
Table 88. Bristol-Myers Squibb Product
Table 89. Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 90. Bristol-Myers Squibb Recent Development
Table 91. Sun Pharmaceuticals Business Overview
Table 92. Sun Pharmaceuticals Product
Table 93. Sun Pharmaceuticals Company Details
Table 94. Sun Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 95. Sun Pharmaceuticals Recent Development
Table 96. Teva Company Details
Table 97. Teva Business Overview
Table 98. Teva Product
Table 99. Teva Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 100. Teva Recent Development
Table 101. Emcure Company Details
Table 102. Emcure Business Overview
Table 103. Emcure Product
Table 104. Emcure Revenue in Malignant Glioma Therapeutics Business (2015-2020) (Million US$)
Table 105. Emcure Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Malignant Glioma Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Radiotherapy Features
Figure 4. Targeted therapy Features
Figure 5. Global Malignant Glioma Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Adult Case Studies
Figure 7. Children Case Studies
Figure 8. Malignant Glioma Therapeutics Report Years Considered
Figure 9. Global Malignant Glioma Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Malignant Glioma Therapeutics Market Share by Regions: 2020 VS 2026
Figure 11. Global Malignant Glioma Therapeutics Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Malignant Glioma Therapeutics Market Share by Players in 2019
Figure 14. Global Top Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Therapeutics as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Malignant Glioma Therapeutics Revenue in 2019
Figure 16. North America Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Asia-Pacific Malignant Glioma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 20. Merck Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 21. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 22. Roche Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 23. Arbor Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Arbor Pharmaceuticals Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 25. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Pfizer Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 27. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. AbbVie Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 29. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Amgen Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 31. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Bristol-Myers Squibb Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 33. Sun Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Sun Pharmaceuticals Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 35. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Teva Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 37. Emcure Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Emcure Revenue Growth Rate in Malignant Glioma Therapeutics Business (2015-2020)
Figure 39. Bottom-up and Top-down Approaches for This Report
Figure 40. Data Triangulation
Figure 41. Key Executives Interviewed